RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-? (GFR?) co-receptors (GFR?1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. In contrast, RET fusion proteins have been reported in papillary thyroid and non-small cell lung adenocarcinomas. More than a dozen fusion partners of RET have been described in papillary thyroid carcinomas, most frequently CCDC6-RET and NCOA4-RET. RET-fusion proteins, commonly KIF5B-RET, have also been found in non-small cell lung cancer (NSCLC). Several drugs targeting RET have been approved by the FDA for the treatment of cancer: cabozantinib and vandetanib for medullary thyroid carcinomas and lenvatinib and sorafenib for differentiated thyroid cancers. In addition, alectinib and sunitinib are approved for the treatment of other neoplasms.
'RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape is provided which includes the disease overview and RET (Ret Proto-Oncogene) protein Inhibitor treatment guidelines. The assessment part of the report embraces, in depth RET (Ret Proto-Oncogene) protein Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RET (Ret Proto-Oncogene) protein Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the RET (Ret Proto-Oncogene) protein Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RET (Ret Proto-Oncogene) protein Inhibitor Emerging Drugs
Further product details are provided in the report……..
RET (Ret Proto-Oncogene) protein Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different RET (Ret Proto-Oncogene) protein Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
RET (Ret Proto-Oncogene) protein Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RET (Ret Proto-Oncogene) protein Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RET (Ret Proto-Oncogene) protein Inhibitor drugs.
RET (Ret Proto-Oncogene) protein Inhibitor Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-? (GFR?) co-receptors (GFR?1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma. In contrast, RET fusion proteins have been reported in papillary thyroid and non-small cell lung adenocarcinomas. More than a dozen fusion partners of RET have been described in papillary thyroid carcinomas, most frequently CCDC6-RET and NCOA4-RET. RET-fusion proteins, commonly KIF5B-RET, have also been found in non-small cell lung cancer (NSCLC). Several drugs targeting RET have been approved by the FDA for the treatment of cancer: cabozantinib and vandetanib for medullary thyroid carcinomas and lenvatinib and sorafenib for differentiated thyroid cancers. In addition, alectinib and sunitinib are approved for the treatment of other neoplasms.
'RET (Ret Proto-Oncogene) protein Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the RET (Ret Proto-Oncogene) protein Inhibitor pipeline landscape is provided which includes the disease overview and RET (Ret Proto-Oncogene) protein Inhibitor treatment guidelines. The assessment part of the report embraces, in depth RET (Ret Proto-Oncogene) protein Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, RET (Ret Proto-Oncogene) protein Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence RET (Ret Proto-Oncogene) protein Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve RET (Ret Proto-Oncogene) protein Inhibitor.
This segment of the RET (Ret Proto-Oncogene) protein Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RET (Ret Proto-Oncogene) protein Inhibitor Emerging Drugs
- Sitravatinib: Mirati Therapeutics
- Zeteletinib: Boston Pharmaceuticals
Further product details are provided in the report……..
RET (Ret Proto-Oncogene) protein Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different RET (Ret Proto-Oncogene) protein Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in RET (Ret Proto-Oncogene) protein Inhibitor
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
RET (Ret Proto-Oncogene) protein Inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RET (Ret Proto-Oncogene) protein Inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RET (Ret Proto-Oncogene) protein Inhibitor drugs.
RET (Ret Proto-Oncogene) protein Inhibitor Report Insights
- RET (Ret Proto-Oncogene) protein Inhibitor Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing RET (Ret Proto-Oncogene) protein Inhibitor drugs?
- How many RET (Ret Proto-Oncogene) protein Inhibitor drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of RET (Ret Proto-Oncogene) protein Inhibitor?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the RET (Ret Proto-Oncogene) protein Inhibitor therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for RET (Ret Proto-Oncogene) protein Inhibitor and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boston Pharmaceuticals
- Mirati Therapeutics
- Sitravatinib
- Voronoi
- GrayBug Vision
- BOS 172738
- Sitravatinib
- Pralsetinib
- VRN-06
- GB 102
Introduction
Executive Summary
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Sitravatinib: Mirati Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
BOS 172738: Boston Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
VRN-06: Voronoi
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
RET (Ret Proto-Oncogene) protein Inhibitor Key Companies
RET (Ret Proto-Oncogene) protein Inhibitor Key Products
RET (Ret Proto-Oncogene) protein Inhibitor- Unmet Needs
RET (Ret Proto-Oncogene) protein Inhibitor- Market Drivers and Barriers
Appendix
Executive Summary
RET (Ret Proto-Oncogene) protein Inhibitor: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Sitravatinib: Mirati Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
BOS 172738: Boston Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
VRN-06: Voronoi
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
RET (Ret Proto-Oncogene) protein Inhibitor Key Companies
RET (Ret Proto-Oncogene) protein Inhibitor Key Products
RET (Ret Proto-Oncogene) protein Inhibitor- Unmet Needs
RET (Ret Proto-Oncogene) protein Inhibitor- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for RET (Ret Proto-Oncogene) protein Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
